



Global Point Prevalence Survey (PPS) – Year 2018 (GLOBAL-PPS)

Note: The aim of this GLOBAL-PPS is to find out what the physicians intend treating and not to base the diagnosis on any case definitions. To obtain this information the primary source should be looking at all [medical, nursing and drug prescription chart] patient records. If the information available is not sufficient surveyor/s may request additional information from nurses, pharmacists or doctors caring for the patient. Searching for information from other sources such a laboratory computer systems, phoning laboratories *etc.*, is not required. **At no point shall there be any discussion about the appropriateness (or lack thereof) of the prescribed medication. The ward staff MUST NOT feel evaluated at the individual level.**

Include in the survey: All patients who are receiving anti-infective agents (ATC codes: J01, J02, A07AA, P01AB, D01BA, J04A, J05 and P01B) and who are in the hospital at 8:00 am on the day of survey should be included in the study.

Prophylaxis: Include any patient who received one or more doses of anti-infective agents intended as surgical prophylaxis in the 24 h prior to 8:00 am on the day of the survey. Checking for any doses administered on the previous day/s will allow the surveyor to code the surgical prophylaxis as either 1 dose, 1 day (multiple doses within 24 hours) or >24hours.

Diagnosis Group: This information is obtained from Appendix II. The conditions are grouped by anatomical site and whether the indication (treatment intent) is prophylaxis or therapeutic.

Global Point Prevalence Survey (2018 GLOBAL-PPS)

Ward Form

Please fill in one form for each ward included in the PPS

Date of survey (dd/mm/year)	_____15_____/____03_____/_____2018_____		
Person completing form (Auditor code)	Ann		
Hospital name	UZA		
Ward Name	Hemato -D4		
Department Type: Place a tick against the type of department	Paediatric departments: <input type="checkbox"/> PMW (Paediatric Medical Ward) <input checked="" type="checkbox"/> HO-PMW (Haematology-Oncology PMW) <input type="checkbox"/> T-PMW (Transplant (BMT/Solid) PMW) <input type="checkbox"/> PSW (Paediatric Surgical Ward) <input type="checkbox"/> PICU (Paediatric Intensive Care Unit) Neonatal departments: <input type="checkbox"/> NMW (Neonatal Medical Ward) <input type="checkbox"/> NICU (Neonatal Intensive Care Unit)		Adult departments: <input type="checkbox"/> AMW (Adult Medical Ward) <input type="checkbox"/> HO-AMW (Haematology-Oncology AMW) <input type="checkbox"/> T-AMW (Transplant (BMT/solid) AMW) <input type="checkbox"/> P-AMW (Pneumology AMW) <input type="checkbox"/> ASW (Adult Surgical Ward) <input type="checkbox"/> AICU ([Adult] Intensive Care Unit)
Mixed Department	X Yes <input type="checkbox"/> No		
Activity: Tick as appropriate. ➤ In case of mixed departments, tick all the encountered activities/specialities	X Medicine	X Surgery	<input type="checkbox"/> Intensive Care
Total number of admitted patients on the ward present at 8.00 am on day of PPS split up by activity. ➤ For mixed departments, fill the total number of patients corresponding to each of the encountered activities.	12	3	
Total number of beds on the ward present at 8:00 am on day of PPS split up by activity. ➤ For mixed departments fill in the total number of beds corresponding to each of the encountered activities.	15	5	

Include only inpatients “admitted before 08:00 hours” on the day of the PPS !



GLOBAL-PPS PATIENT Form (Please fill in one form per patient on antimicrobial treatment/prophylaxis)

Ward Name/code	Activity ¹ (M, S, IC)	Patient Identifier ²	Survey Number ³	Patient Age ⁴			Weight In kg, 2 decimals	Gender M or F			
				Years (if ≥ 2 years)	Months (1-23 month)	Days (if <1 month)					
Hemato – D4	M	12345678		16			51.5	M			
Antimicrobial Name ⁵		1. Meropenem		2. Co-trimoxazole		3. Teicoplanin		4. Amikacin		5.	
Single Unit Dose ⁶	Unit (g, mg, or IU) ⁷	770	mg	480	mg	400	Mg	500	mg		
Doses/ day ⁸	Route (P, O, R, I) ⁹	3	P	1	O	1	P	1	P		
Diagnosis ¹⁰ (see appendix II)		Sepsis		MP		Sepsis		Sepsis			
Type of indication ¹¹ (see appendix III)		HAI2		MP		HAI2		HAI2			
Reason in Notes (Yes or No) ¹²		No		No		No		No			
Guideline Compliance (Y, N, NA, NI) ¹³		N		Y		Y		Y			
Is a stop/review date documented?(Yes/No)		No		No		No		Yes			
Treatment (E: Empirical; T: Targeted)		T		E		T		T			
The next section is to be filled in only if the treatment choice is based on microbiology data (Treatment=targeted) AND the organism is one of the following											
MRSA (Yes or No) ¹⁴						Yes					
MRCoNS (Yes or No) ¹⁵											
VRE (Yes or No) ¹⁶											
ESBL-producing Enterobacteriaceae (Yes or No) ¹⁷		Yes						Yes			
3rd generation cephalosporin resistant Enterobacteriaceae non-ESBL producing or ESBL status unknown (Yes or No)											
Carbapenem-resistant Enterobacteriaceae (Yes or No) ¹⁸											
ESBL-producing non fermenter Gram-negative bacilli (Yes or No) ¹⁹											
Carbapenem-resistant non fermenter Gram-negative bacilli (Yes or No) ²⁰											
Targeted treatment against other MDR organisms (Yes or No) ²¹											
Treatment based on biomarker data (Yes or No)		X Yes – 0 No									
If yes, which biomarker (CRP, PCT or other) ²²	CRP	Type of biological fluid sample (Blood/urine/other)	Blood	Most relevant value of biomarker on the day of the PPS							
				Value				Unit (in µg/L, mg/L, ...) ²³			
				215				mg/L			



- ¹ Activity: M=medicine (including Psychiatric cases, *etc.*), S=surgery (including orthopaedics, obstetrics and gynaecology, *etc.*), IC=intensive care
- ² Patient Identifier: A unique patient identifier that allows linkage to patient records at local level for more detailed audit. This unique identifier will not be included in the online database.
- ³ Survey Number: A unique non-identifiable number given by WebPPS for each patient entered in the database. Leave blank but note down the number after the patient data has been recorded in the online database. The number is displayed once (and only) after the patient data has been recorded in the online database.
- ⁴ Patient Age: If the patient is 2 years old or older, specify only the number of years, if between 1 and 23 months specify only the number of months, if less than 1 month specify the number of days.
- ⁵ Antimicrobial Name: Insert generic name.
- ⁶ Single Unit Dose: Numeric value for dose per administration (in grams, milligrams or IU).
- ⁷ Unit: The unit for the dose (g, mg or IU)
- ⁸ Doses/day: If necessary provide fractions of doses: (e.g., every 16h = 1.5 doses per day, every 36h = 0.67 doses per day, every 48h = 0.5 doses per day)
- ⁹ Route: Routes of administration are: Parenteral (P), Oral (O), Rectal (R), Inhalation (I).
- ¹⁰ See diagnoses groups list (Appendix II)
- ¹¹ See Indication codes (Appendix III)
- ¹² Reason in Notes: A diagnosis / indication for treatment is recorded in the patient's documentation (treatment chart, notes, etc.) at the start of antibiotic treatment (Yes or No)
- ¹³ Guideline Compliance: Refers to antibiotic choice (not route, dose, duration etc) in compliance with local guidelines (Y: Yes; N: No; NA: Not assessable because no local guidelines for the specific indication; NI: no information because indication is unknown)
- ¹⁴ Methicillin-resistant *Staphylococcus aureus* (MRSA)
- ¹⁵ Methicillin-resistant coagulase negative staphylococci (MRCoNS)
- ¹⁶ Vancomycin-resistant enterococci (VRE)
- ¹⁷ Bacteria, producing extended-spectrum beta-lactamases (ESBL)
- ¹⁸ Carbapenem-resistant *Enterobacteriaceae* (CRE) – enteric bacteria resistant to imipenem, meropenem or other carbapenems
- ¹⁹ Nonfermenters: *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Burkholderia spp.*, *Stenotrophomonas maltophilia*
- ²⁰ Carbapenem-resistant Nonfermenters (CR-NF) – nonfermenters resistant to imipenem, meropenem or other carbapenems
- ²¹ Multi-drug resistant (MDR) pathogens, others than the listed above.
- ²² If treatment based on biomarker, specify which one: CRP (C-reactive protein), PCT (Procalcitonin) or Other (=lab-based culture and sensitivity result from a relevant biological sample)
- ²³ The unit for the biomarker CRP or PCT value expressed in mg/l, µg/L, ng/L, mg/dL, ng/dL, ng/mL, µg/mL, nmol/L. For a conversion calculator see: <http://unitslab.com/node/67> (CRP) and <http://unitslab.com/node/103> (procalcitonin)



Appendix I: Combination anti-infective agents

Combinations of an antibiotic and an enzyme inhibitor:

Ampicillin and enzyme inhibitor: **report only ampicillin dose** (J01CR01)

Amoxicillin and enzyme inhibitor: **report only amoxicillin dose** (J01CR02)

Ticarcillin and enzyme inhibitor: **report only ticarcillin dose** (J01CR03)

Piperacillin and enzyme inhibitor: **report only piperacillin dose** (J01CR05)

Imipenem and enzyme inhibitor: **report only imipenem dose** (J01DH51)

Panipenem and betamipron: **report only panipenem** (J01DH55)

Example:

Augmentin® 1.2g IV → 1g (amoxicillin) + 200mg (clavulanic acid), **report only 1 g**

Piperacillin® 4.5g IV → 4g (piperacillin) + 500mg (tazobactam), **report only 4 g**

Other combinations of multiple antimicrobial substances:

J01EE01 Sulfamethoxazole and Trimethoprim: report the total amount of sulfamethoxazole and trimethoprim

Example:

Co-trimoxazole 960mg: (sulfamethoxazole. 800mg + trimethoprim 160mg), **report 960mg**

Further information on agents included for the Global-PPS is available in the antimicrobial list. Only antimicrobial substance name need to be written down, NOT the ATC codes! (excel file - available at website under documents: Global-PPS_antimicrobial_list.xlsx)

<http://www.global-pps.com/>



Appendix II - Diagnostic codes (what the clinician aims at treating)

Site	Codes	Examples
CNS	Proph CNS	Prophylaxis for CNS (neurosurgery, meningococcal)
	CNS	Infections of the C entral N ervous S ystem
EYE	Proph EYE	Prophylaxis for Eye operations
	EYE	Therapy for Eye infections e.g., Endophthalmitis
ENT	Proph ENT	Prophylaxis for E ar, N ose, T hroat (S urgical or M edical prophylaxis= SP/MP)
	ENT	Therapy for E ar, N ose, T hroat infections including mouth, sinuses, larynx
RESP	Proph RESP	Pulmonary surgery, prophylaxis for R espiratory pathogens e.g. for aspergillosis
	LUNG	Lung abscess including aspergilloma
	URTI	U pper R espiratory T ract viral I nfections including influenza but not ENT
	Bron	Acute B ronchitis or exacerbations of chronic bronchitis
	Pneu	P neumonia or LRTI (lower respiratory tract infections)
	TB	Pulmonary TB (Tuberculosis)
CVS	Proph CVS	C ardiac or V ascular Surgery, endocarditis prophylaxis
	CVS	C ardio V ascular S ystem infections: endocarditis, endovascular prosthesis or device e.g pacemaker, vascular graft
GI	Proph GI	Surgery of the G astro- I ntestinal tract, liver or biliary tree, GI prophylaxis in neutropaenic patients or hepatic failure
	GI	GI infections (salmonellosis, <i>Campylobacter</i> , parasitic, <i>C.difficile</i> , etc.)
	IA	I ntra- A bdominal sepsis including hepatobiliary, intra-abdominal abscess etc.
SSTBJ	Proph BJ	Prophylaxis for SST, for plastic or orthopaedic surgery (B one or J oint)
	SST	S kin and S oft Tissue: Cellulitis, wound including surgical site infection, deep soft tissue not involving bone e.g., infected pressure or diabetic ulcer, abscess
	BJ	B one/ J oint Infections: Septic arthritis (including prosthetic joint), osteomyelitis
UTI	Proph UTI	Prophylaxis for urological surgery (SP) or recurrent U rinary T ract I nfection (MP)
	Cys	Lower UTI
	Pye	Upper UTI including catheter related urinary tract infection, pyelonephritis
GUOB	Proph OBGY	Prophylaxis for OB stetric or GY naecological surgery
	OBGY	OB stetric/ GY naecological infections, S exual T ransmitted D iseases (STD) in women
	GUM	GE nito- U rinary M ales + Prostatitis, epididymo-orchitis, STD in men
No defined site (NDS)	BAC	Bacteraemia with no clear anatomic site and no shock
	SEPSIS	Sepsis, sepsis syndrome or septic shock with no clear anatomic site
	Malaria	
	HIV	Human immunodeficiency virus
	PUO	P yrexia of U nknown O rigin - Fever syndrome with no identified source or site of infection
	PUO-HO	Fever syndrome in the non-neutropaenic H aematology- O ncology patient with no identified source of pathogen
	FN	F ever in the N eutropenic patient
	LYMPH	Infection of the l ymphatics as the primary source of infection e.g. suppurative lymphadenitis
	Other	Antibiotic prescribed with documentation for which there is no above diagnosis group
	MP-GEN	Drug is used as M edical P rophylaxis in g eneral, without targeting a specific site, e.g. antifungal prophylaxis during immunosuppression
	UNK	Completely U nknown Indication
PROK	Antimicrobial (e.g. erythromycin) prescribed for P rokinetic use	
Neonatal	MP-MAT	Drug is used as M edical P rophylaxis for M ATERNAL risk factors e.g. maternal prolonged rupture of membranes
	NEO-MP	Drug is used as M edical P rophylaxis for N EWBORN risk factors e.g. VLBW (Very Low Birth Weight) and IUGR (Intrauterine Growth Restriction)



APPENDIX III - Type of Indication

CAI Community acquired infection	Symptoms started <48 hours from admission to hospital (or present on admission).		
HAI Healthcare-Associated Infection ➤ Symptoms start 48 hours after admission to hospital	HAI1 Post-operative surgical site infection (within: 30 days of surgery OR; 1 year after implant surgery)		
	HAI2 Intervention related infections including CR-BSI, VAP and C-UTI		
	HAI3 <i>C. difficile</i> associated diarrhoea (CDAD) (>48 h post-admission or <30 days after discharge from previous admission episode).		
	HAI4 Other hospital acquired infection (includes HAP, etc)		
	HAI5 Infection present on admission from another hospital (patient with infection from another hospital)		
	HAI6 Infection present on admission from long-term care facility (LTCF) or Nursing Home*.		
SP Surgical prophylaxis	SP1 Single dose	SP2 one day	SP3 >1 day
For surgical patients , administration of prophylactic antimicrobials should be checked in the previous 24 hours in order to encode the duration of prophylaxis as either one dose, one day (= multiple doses given within 24 hours) or >1 day. See more explanation in protocol page 6 and 7 !			
MP Medical prophylaxis	For example long term use to prevent UTI's or use of antifungals in patients undergoing chemotherapy or penicillin in asplenic patients etc.		
OTH Other	For example erythromycin as a motility agent (motilin agonist).		
UNK	Completely unknown indication		

Select 1 possibility for each reported antimicrobial

CR-BSI= Catheter related-Blood Stream Infection

C-UTI= Catheter related-Urinary Tract Infection

HAP=Hospital Acquired Pneumonia

VAP=Ventilator Associated Pneumonia

* Long-term care facilities represent a heterogeneous group of healthcare facilities, with care ranging from social to medical care. These are places of collective living where care and accommodation is provided as a package by a public-agency, non-profit or private company (e.g. nursing homes, residential homes).

